x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

DarshanTalks Podcast

Darshan Kulkarni

Welcome to DarshanTalks!We demystify fraud for legal, regulatory, and compliance essentials in the life sciences and pharmacy industries. Through engaging 15-30-minute interviews with influential change makers, short educational regulatory defbriefs, and 60 second audio takeaways, we unveil the strategies behind bringing drugs and devices to market—and keeping them there!Powered By The Kulkarni Law Firm - Helping regulators see your business the way you do.We focus on life science issues involving

science life sciences

All Episodes

7:57

The Hidden Reason Sites are Firing Recruiters

DarshanTalks Podcast ·

2026/04/11

Send us Fan Mail What would happen if your clinical trial sites were suddenly banned from using you? In this episode, Darshan Kulkarni uncovers a hidden regulatory shift: state licensing boards are tightening the "Corporate Practice of Medicine" and "Fee Splitting" laws. If your recruitment fees are tied to enrollment or revenue, you aren't just a vendor—you’re a legal liability. We break down the MSO structures that are failing, the "Red Zones" in state law, and how KLF re-architects y...

en-us

1:06

Don’t Let Your PI Walk Away With Your Study

DarshanTalks Podcast ·

2026/04/10

Send us Fan Mail In this tactical masterclass, Darshan Kulkarni breaks down the critical legal architecture required to protect clinical trial sites during rapid expansion. As PIs and Sub-Investigators move between organizations, the risk of losing proprietary data and patient continuity skyrockets. Learn the specific clauses—from non-solicitation to transition requirements—that ensure your site retains its value and your sponsors remain confident. Don't let your most valuable assets wa...

en-us

2:24

Safe or Just "Not Dirty"? The Regulatory Gamble of...

DarshanTalks Podcast ·

2026/04/09

Send us Fan Mail In this episode, Darshan Kulkarni breaks down the staggering legal difference between the branded drugs you know (like Mounjaro) and the compounded versions flooding the market. Using a brilliant "Coke vs. RC Cola" analogy, we explore why "clean vats" aren't the same as "proven science." If you are a patient, a provider, or a legal professional in the life sciences space, you need to understand the four pillars of FDA approval—and why some of the most popular drugs on t...

en-us

3:51

"Basically Employees" Isn't a Legal Category (And the...

DarshanTalks Podcast ·

2026/04/06

Send us Fan Mail Stop playing compliance theater. In this episode, Darshan Kulkarni pulls back the curtain on a dangerous trend in the life sciences: the over-reliance on contract sales forces without the legal control to back them up. Many companies believe they’ve "solved" the incentive pay problem, only to realize the OIG hasn't changed its mind since 1998. We break down why the "Pikachu face" won't save you when the government comes knocking, the myth of the "basically an employee" legal ...

en-us

0:45

The Hidden Legal Risks of AI Sponsor Protocols

DarshanTalks Podcast ·

2026/04/03

Send us Fan Mail Is AI the savior of clinical research costs, or a ticking time bomb for data integrity? In this episode, Darshan Kulkarni dives into the murky waters of AI-driven sponsor protocols. We explore how AI is being used to mask—and unmask—data falsification, and what life science sponsors must do to ensure compliance before the regulators knock. If you’re using AI to "make life easier," you might be making your legal defense much harder. Support the show www.kulkarnilaw...

en-us

3:26

The $100M Mistake: Why AI-Generated Drugs May Not Be...

DarshanTalks Podcast ·

2026/04/02

Send us Fan Mail "The model said so" is not a defense. In the rush to integrate AI into drug discovery, life science companies are sprinting toward a compliance cliff. In this episode, Darshan Kulkarni—pharmacist and FDA regulatory lawyer—strips away the marketing hype to reveal the "messy reality" of AI in regulated environments. We dive deep into the three pillars of risk that can sink a biotech firm: Data Integrity: Why AI scales bad data faster than you can fix it.The Ownership Crisis: Wh...

en-us

12:57

Is AI replacing your Doctor?

DarshanTalks Podcast ·

2026/03/30

Send us Fan Mail In this episode of DarshanTalks, host and attorney-pharmacist Darshan Kulkarni explores the unsettling transition from "Googling your symptoms" to "Chatting with your symptoms." It’s 10:47 PM—you have chest tightness and a chatbot is your only companion. But is the algorithm reassuring you, or is it gaslighting a medical emergency? We go beyond the hype to examine the February 9, 2026, Nature Medicine study (as reported in the New York Times) which reveals a staggering gap be...

en-us

0:53

Why the OIG Just Revolutionized Pharma Marketing (And...

DarshanTalks Podcast ·

2026/03/28

Send us Fan Mail On January 27, 2026, the HHS Office of Inspector General (OIG) changed the game for pharmaceutical manufacturers. In a landmark Special Advisory Bulletin, the government officially opened a "green lane" for direct-to-patient (DTP) drug sales, specifically addressing the rise of cash-pay programs like TrumpRx. In this episode, we break down why the OIG is now prioritizing lower costs over traditional Anti-Kickback Statute (AKS) risks for cash-paying patients—including th...

en-us

0:42

6 Categories of "Bulk Data" That Could Land You in...

DarshanTalks Podcast ·

2026/03/27

Send us Fan Mail The DOJ just changed the rules of the game for the Life Sciences industry. As of January 2025, transferring "Bulk Sensitive Personal Data" to countries of concern—specifically China—is no longer just a compliance hurdle; it’s a potential federal violation. In this episode, Darshan Kulkarni breaks down the six categories of data you must protect immediately, from genomic data to precise geolocation. If you are handling safety data across borders, this is your mandatory executi...

en-us

1:39

The Utah Experiment: The Dangerous New Frontier of AI...

DarshanTalks Podcast ·

2026/03/26

Send us Fan Mail Is your state "sandbox" a playground or a legal minefield? In this episode, Darshan Kulkarni—pharmacist and attorney—dissects the quiet movement of states like Utah allowing AI to manage and renew prescriptions. While the innovation is exciting, the federal government is watching closely. We break down the three massive risks facing life science companies and healthcare providers today: Clinical Logic Failures: Why a state sandbox can't fix bad AI medicine.The Liability Void:...

en-us

3:28

Is Your DTC Program a Kickback Trap?

DarshanTalks Podcast ·

2026/03/23

Send us Fan Mail The OIG has officially shifted the goalposts for Direct-to-Consumer (DTC) and Direct-to-Patient (DTP) programs. For years, federal healthcare discounts were a "no-go zone," but a new dual-track strategy is emerging—if you know how to build the firewall. In this episode, Darshan Kulkarni breaks down the three core regulatory pillars required to bypass PBM middlemen without triggering federal anti-kickback statutes. We discuss the "one-year commitment" rule, the "seeding"...

en-us

0:33

The Hidden Death Sentence for Trial Sites

DarshanTalks Podcast ·

2026/03/20

Send us Fan Mail In this episode of KLF Deep Dive, Darshan Kulkarni uncovers the catastrophic risks clinical trial sites face when they fail to vet their staff against federal exclusion lists. We move beyond simple compliance to discuss the "off-the-books" penalties that can end a career or a company. If you’re in the life sciences, this is the legal shield you can't afford to ignore. Support the show www.kulkarnilawfirm.com

en-us

9:30

FDA "Screams": The Real Reason Your Snack Is At Risk

DarshanTalks Podcast ·

2026/03/19

Send us Fan Mail Undeclared allergens remain the #1 cause of food recalls in the U.S., yet many brands still treat labeling as a "marketing" task rather than a "legal" one. In this episode of KLF Deep Dive, Darshan Kulkarni breaks down the regulatory horror stories of major brands—from Nugo to Frito-Lay—and explains why the FDA doesn't care if your co-manufacturer messed up. If your name is on the bag, you own the risk. Learn how to transition from "marketing font arguments" to FSMA-compliant...

en-us

2:49

2 Laws More Dangerous Than HIPAA for Patient Engagement

DarshanTalks Podcast ·

2026/03/16

Send a text Think HIPAA is your biggest hurdle in pharma marketing? Think again. In this episode of KLF Deep Dive, Darshan Kulkarni reveals why focusing solely on HIPAA leaves a massive, unregulated gap in your compliance strategy. We break down the "layered system" of risk—from aggressive state privacy laws and medical privacy statutes to the DOJ’s massive 2025 Bulk Data Rule. Whether you’re running patient engagement campaigns or leveraging marketing automation, you’ll learn why the t...

en-us

3:14

"Invite-Only" Compliance Is Over: Is Your Cosmetic...

DarshanTalks Podcast ·

2026/03/14

Send a text The "handshake" era of cosmetic compliance is officially over. Under new authorities in Sections 605, 610, and 704, the FDA has moved from simple observation to an aggressive "access and copy" mandate. In this episode, Darshan Kulkarni breaks down the "SAHCOD" threat and explains why your internal communications, medical assessments, and even cross-contamination logs are now fair game for federal investigators. If you handle raw materials or shared manufacturing equipment, y...

en-us

0:46

Audit-Proof Your Site: The Training Gap Killing Your...

DarshanTalks Podcast ·

2026/03/13

Send a text In clinical research, if it isn't documented, it never happened. Many site owners mistake a competent team for a compliant one—a mistake that leads to disastrous FDA inspections and lost sponsor contracts. In this KLF Deep Dive, Darshan Kulkarni reveals the specific training SOPs, log templates, and contract clauses required to protect your site. Learn how to bridge the gap between "doing the work" and "proving the work" so you can demonstrate a culture of readiness that spo...

en-us

2:49

15 Years in Prison for Marketing Fraud

DarshanTalks Podcast ·

2026/03/12

Send a text Is your marketing team building a brand or a federal case? In this episode, we deconstruct the $1.2 billion collapse of Boom Care. What looked like a runaway success story in the wound care space was actually a systematic violation of the False Claims Act. We break down the three fatal mistakes that led to 15-year prison sentences for executives: prioritizing reimbursement over medical necessity, incentivizing volume over value, and treating compliance as an afterthought. If...

en-us

3:34

Is your "Clinical Decision Support" tool actually an...

DarshanTalks Podcast ·

2026/03/11

Send a text In January 2026, the FDA sharpened the line between helpful software and regulated medical devices. If your AI sits inside an EHR, providing "black box" recommendations that a clinician can’t independently verify in seconds, you aren't just drifting into a regulatory gray area, you’re likely standing outside the "safe zone." In this episode, we break down the high-stakes intersection of FDA transparency, OIG inducement analysis, and the reality of clinical workflows. In this episo...

en-us

4:48

The FDA’s New Political Enforcement Strategy

DarshanTalks Podcast ·

2026/03/10

Send a text In this episode, Darshan Kulkarni exposes a massive legal shift that is quietly dismantling the "Practice of Medicine" defense. We track the whiplash from the 2021 Ivermectin court victories to the DOJ’s aggressive 2025 memorandum targeting gender-affirming care. Is "Intended Use" being weaponized as a high-tech surveillance tool? If the government can criminalize the intent behind a legal hormone, what does that mean for every manufacturer and physician operating in the off-label...

en-us

22:57

Why Your "Physician-Only" Ads Aren't Safe from...

DarshanTalks Podcast ·

2026/03/09

Send a text In this episode of the KLF Deep Dive, Darshan Kulkarni sits down with Phyllis Marcus, Vice President of the National Advertising Division (NAD) and former FTC veteran. They unpack the complex "grey area" where healthcare professional (HCP) communications bleed into the public consumer space. Phyllis reveals why labeling an ad "For Healthcare Professionals Only" may no longer protect a company from regulatory scrutiny and explains the NAD’s role as an independent adjudicator ...

en-us

330 results

Similar Podcasts

Classic Radio Science Fiction

solgoodmedia.com

Mission to Mars

Inception Point Ai

The 365 Days of Astronomy

365DaysOfAstronomy.org

Creek Devil

william Jevning

UFO Chronicles Podcast

Nik Hunter